KR930021179A - 염증 및 창상 치료를 위한 플라스미노겐 활성화제 억제제의 용도 - Google Patents

염증 및 창상 치료를 위한 플라스미노겐 활성화제 억제제의 용도 Download PDF

Info

Publication number
KR930021179A
KR930021179A KR1019930007154A KR930007154A KR930021179A KR 930021179 A KR930021179 A KR 930021179A KR 1019930007154 A KR1019930007154 A KR 1019930007154A KR 930007154 A KR930007154 A KR 930007154A KR 930021179 A KR930021179 A KR 930021179A
Authority
KR
South Korea
Prior art keywords
treatment
eye
use according
corneal
edema
Prior art date
Application number
KR1019930007154A
Other languages
English (en)
Inventor
쉴러 엑크하르트
뢰미쉬 위르겐
패커스 에릭-폴
딕크나이테 게르하르트
Original Assignee
슈타인, 북크
베링베르케 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 슈타인, 북크, 베링베르케 아크티엔게젤샤프트 filed Critical 슈타인, 북크
Publication of KR930021179A publication Critical patent/KR930021179A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명은 손상의 치료 및 염증성 장애의 치료 및 예방을 위한, 수술중간 및 수술후의 치료를 위한 플라스미노겐 활성화제의 억제제(예: 유로키나제, uPA 또는 tPA)에 관한 것이다.
특히 적합한 억제제는 PAI-1 및 PAI-2이다.

Description

염증 및 창상 치료를 위한 프라스미노겐 활성화제 억제제의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (22)

  1. 눈, 귀, 피부, 골절, 내장 또는 기타 내부기관의 치료 및/또는 수술 도중 및/또는 수술 후의 치료 및/또는 개방된 창상을 치료하기 위한 약제를 제조하기 위한 프라스미노게 활성화제 억제제의 용도.
  2. 제1항에 있어서, 플라스미노겐 활성화제가 유로키나제 및/또는 tPA인 용도.
  3. 제1항에 있어서, 억제제가 PAI-1 또는 PAI-2, 바람직하게는 PAI-2의 단편인 용도.
  4. 제1항에 있어서, 각막 궤양, 포도막염, 결막염, 중이염, 고막염, 염증으로 인한 고막 파열, 피부의 홍반, 유극층위축, 천포창, 습진, 접촉성 피부염, 과민성 피부염, 염증이 생긴 화상, 맥관염, 피부궤양, 골관절염, IBD(염증성 장 질병), 췌장염, 좌창의 치료, 상피 손상의 치료, 각막 손상의 치료, 눈 손상시 발생하는 반흔의 치료, 공막염, 불치 각막 침식, 건조증 및/또는 각화증의 치료를 위한 용도.
  5. 제1항에 있어서, 수술 도중 및 수술후의 치료 및/또는 염증이 생긴 개발된 창상의 치료를 위한 용도.
  6. 제1항에 있어서, 혈관신생을 억제하고, 콘텍트 렌즈 착용자의 눈의 각막 침윤 또는 각막 염증을 치료하기 위한 용도.
  7. 제1항에 있어서, 수술 치료가 레이저 각막절제술이고/ 이거나 개방된 창상 또는 염증이 레이저 각막절제술의 결과인 용도.
  8. 제1항에 있어서, 레이저 치료, 통상의 눈수술(예를 들면, 유리체절제술, 백내장수술, 낭외 백내장 척출, 수정체 수술, 수정체 대체, 수정체 내이식, 결막염, 각막 이식)후 눈의 염증 및 눈의 혼탁, 결막염, 각결막염, 건성각결막염, 홍채염, 홍채모양체염, 각막염, 그레이브스 눈병(Grave's ophtrhalmopathy), 모어 궤양(Mooren's ulcer), 맥관염, 포도막염, 눈에서의 알러지성 발현, 감염, 대사성장애, 염증 질병 및 자동면역 질병〔예를들면, 전신 홍반성낭창, 베그너육아종증(Wegner's granulomatosis), 류마티스성 관절염, 유육종종, 다중관절영, 천포창, 유천포창, 다형성홍진, 쇼그렌증후(Siogren's syndrome), 염증성 장 질병, 다발성 경화증, 위마비성근무력증, 각막염, 공막염〕의 치료를 위한 용도.
  9. 제1항에 있어서, 수술 후 또는 손상 후 눈의 반흔을 방지하기 위한 용도.
  10. 제1항에 있어서, 특히 당뇨병에서의 망막증시 발생하는 혈관신생을 억제하고, 분리된 망막, 망막 혈관 손상 또는 망막 및 포도막의 염증, 또는 각막 이식에 사용되는 용도.
  11. 제1항에 있어서, 눈의 이식, 특히 각막 이식에 사용되는 용도.
  12. 제1항에 있어서, 눈 부위의 부종, 예를 들면, 반점부종, 경증 반점 부종, 광응고후의 부종, 각막 부종, 결막 부종, 망막 부종, 누 주변의 부종의 치료를 위한 용도.
  13. 제1항에 있어서, 눈 부위, 특히 각막, 안방(chamber of the eye), 결막 및 공막의 침윤을 치료하기 위한 용도.
  14. 제1항에 있어서, 특히 안과학에서의 창상 치유 속도를 증가시키는 용도.
  15. 제1항에 있어서, 국소 주사, 예를 들면, 결막 아래, 유리체, 안방 또는 공막내로 주사되는 용도.
  16. 제1항에 있어서, 미세 주사로 투여되는 용도.
  17. 제1항에 있어서, 세정 용액으로서 사용되는 용도.
  18. 제1항에 있어서, 생분해성 비히클 시스템과 병용되는 억제제의 용도.
  19. 제1항에 있어서, 약제학적으로 허용되는 담체 시스템, 예를 들면, 셀룰로오즈 유도체, 중합체성 매트릭스 또는 콘텍트 렌즈와 병용되는 억제제의 용도.
  20. 제1항에 있어서, 가용화제와 병용되는 억제제의 용도.
  21. 제1항에 있어서, 다른 활성물질과 병용되는 억제제의 용도.
  22. 제1항에 있어서, 하나 이상의 항생제가 다른 활성물질로서 사용되는 억제제의 용도.
    ※ 참고사항: 최초출원 내용에 의하여 공개하는 것임
KR1019930007154A 1992-04-30 1993-04-28 염증 및 창상 치료를 위한 플라스미노겐 활성화제 억제제의 용도 KR930021179A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4214215.6 1992-04-30
DE4214215A DE4214215A1 (de) 1992-04-30 1992-04-30 Verwendung von inhibitoren von plasminogenaktivatoren zur behandlung von entzuendungen

Publications (1)

Publication Number Publication Date
KR930021179A true KR930021179A (ko) 1993-11-22

Family

ID=6457814

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930007154A KR930021179A (ko) 1992-04-30 1993-04-28 염증 및 창상 치료를 위한 플라스미노겐 활성화제 억제제의 용도

Country Status (16)

Country Link
EP (1) EP0567816A1 (ko)
JP (1) JPH069425A (ko)
KR (1) KR930021179A (ko)
CN (1) CN1080873A (ko)
AU (1) AU3822993A (ko)
CA (1) CA2095207A1 (ko)
CZ (1) CZ76893A3 (ko)
DE (1) DE4214215A1 (ko)
HU (1) HUT65755A (ko)
IL (1) IL105521A0 (ko)
MX (1) MX9302519A (ko)
NO (1) NO931561L (ko)
PL (1) PL298748A1 (ko)
SK (1) SK41593A3 (ko)
UY (1) UY23572A1 (ko)
ZA (1) ZA933023B (ko)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5468505A (en) * 1992-02-28 1995-11-21 Board Of Regents, The University Of Texas System Local delivery of fibrinolysis enhancing agents
GB2271507A (en) * 1992-09-04 1994-04-20 Summit Technology Ireland Bv Compositions containing plasmin activity inhibitors
US5994341A (en) * 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
DE69434048T2 (de) * 1993-07-19 2005-10-06 Angiotech Pharmaceuticals, Inc., Vancouver Anti-angiogene Mittel und Verfahren zu deren Verwendung
US6558798B2 (en) 1995-02-22 2003-05-06 Scimed Life Systems, Inc. Hydrophilic coating and substrates coated therewith having enhanced durability and lubricity
US5939525A (en) * 1995-03-27 1999-08-17 Viron Therapeutics, Inc. Methods of treating inflammation and compositions therefor
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US20040254635A1 (en) 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
JP2002526382A (ja) * 1998-04-01 2002-08-20 バイオテック・オーストラリア・ピーティーワイ・リミテッド 皮膚創傷の治療へのプロテアーゼ阻害剤の使用
US6293967B1 (en) 1998-10-29 2001-09-25 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
WO2000066139A2 (en) * 1999-04-29 2000-11-09 Ista Pharmaceuticals, Inc. Biochemical methods that eliminate corneal scars, opacification and haze
US6156373A (en) 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
JP3690720B2 (ja) 1999-09-14 2005-08-31 インターナショナル・ビジネス・マシーンズ・コーポレーション クライアントサーバーシステム、オブジェクトのプール方法および記憶媒体
PT1223971E (pt) 1999-10-27 2005-10-31 Alexandra Lucas Composicoes e metodos para prevencao e tratamento da rejeicao de transplante
JP2001247458A (ja) * 2000-03-08 2001-09-11 Hamari Chemicals Ltd トラネキサム酸亜鉛化合物を含む糖尿病治療剤
AU2001291579B2 (en) 2000-09-29 2006-08-31 Viron Therapeutics Inc. Use of serp- 1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
KR100819895B1 (ko) 2000-10-16 2008-04-07 코너 메드시스템즈 인코포레이티드 약제 전달용 팽창 가능한 의료 장치
US6764507B2 (en) 2000-10-16 2004-07-20 Conor Medsystems, Inc. Expandable medical device with improved spatial distribution
US20040073294A1 (en) 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
AT500019B1 (de) * 2001-06-27 2007-06-15 Inst Gefaessbiologie Und Throm Verwendung in vitro des transkriptionsfaktors nak-1 oder von nak-1 regulierten genen zur diagnose von entzündlichen und malignen erkrankungen
GB0126389D0 (en) * 2001-11-02 2002-01-02 Pfizer Ltd Wafer
US7785653B2 (en) 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
US20090202524A1 (en) * 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders
BRPI0906167A2 (pt) * 2008-01-21 2018-05-22 Dermadis S A uso de inibidor de serina protease no tratamento de doenças de pele.
TWI763960B (zh) * 2017-12-15 2022-05-11 大陸商深圳瑞健生命科學研究院有限公司 一種預防或治療骨關節炎的方法及藥物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3829523A1 (de) * 1988-08-31 1990-03-01 Behringwerke Ag Verwendung von plasminogen-aktivator-inhibitor (pai-2) zur immunsuppression
DK0458937T3 (da) * 1989-12-20 1998-02-23 Biotech Australia Pty Ltd Varianter af PAI-2
EP0451130A3 (en) * 1990-04-05 1992-08-05 Baltimore Biotech, Inc. Use of amiloride and other pyrazine derivatives for preventing or treating ocular neovascularization

Also Published As

Publication number Publication date
HUT65755A (en) 1994-07-28
MX9302519A (es) 1993-10-01
NO931561L (no) 1993-11-01
AU3822993A (en) 1993-11-04
SK41593A3 (en) 1993-11-10
IL105521A0 (en) 1993-08-18
ZA933023B (en) 1994-10-31
NO931561D0 (no) 1993-04-29
UY23572A1 (es) 1993-05-04
EP0567816A1 (de) 1993-11-03
DE4214215A1 (de) 1993-11-04
PL298748A1 (en) 1993-12-27
HU9301272D0 (en) 1993-07-28
CN1080873A (zh) 1994-01-19
CZ76893A3 (en) 1994-01-19
JPH069425A (ja) 1994-01-18
CA2095207A1 (en) 1993-10-31

Similar Documents

Publication Publication Date Title
KR930021179A (ko) 염증 및 창상 치료를 위한 플라스미노겐 활성화제 억제제의 용도
CA2211376C (en) Bio-erodible ophthalmic shield
Ruiz et al. Management of increased intraocular pressure after cataract extraction
Jaffe et al. Treatment of postvitrectomy fibrin pupillary block with tissue plasminogen activator
Kenyon Decision-making in the therapy of external eye disease: noninfected corneal ulcers
Aquavella et al. Use of collagen shields as a surgical adjunct
Burke et al. Comparison of the effects of two viscoelastic agents, Healon and Viscoat, on postoperative intraocular pressure after penetrating keratoplasty
US4444787A (en) Ophthalmic topical use of collagen cross-linking inhibitors
Khan et al. Examine the Comparison of Efficacy Between Intracameral and Sub Conjuctival Dexamethasone for the Prevention of Postoperative Inflammation in Patients with Cataract Surgery
WO1995018604A1 (en) Topical treatment of ocular photophobia
Zarei et al. Inhibition of intraocular fibrin formation after infusion of low-molecular-weight heparin during combined phacoemulsification–trabeculectomy surgery
Takahashi et al. Antiproliferative effect of retinoic acid in 1% sodium hyaluronate in an animal model of PVR
RU2268722C2 (ru) Способ лечения и профилактики глазных болезней, связанных с ишемией тканей глаза
Macky et al. Viscoanesthesia: Part II: toxicity to intraocular structures after phacoemulsification in a rabbit model
RU2284181C2 (ru) Фармацевтическая композиция для профилактики инфекции в офтальмологии "интрависк"
Holland et al. Chemical and thermal injuries to the ocular surface
EP0540747B1 (en) Medicine for intraocular operation
Saji Nair et al. Bandage contact lens: a clinical study
RU2163123C2 (ru) Глазные капли
Gou et al. Mechanism and Treatment of Secondary Glaucoma after Corneal Transplantation: A Review
Pinter et al. Corneal degeneration after silicone oil tamponade in a photorefractive keratectomy treated eye
RU2198635C1 (ru) Способ профилактики рецидива эрозии и изъязвления роговицы при двусторонних ожогах глаз
RU2008866C1 (ru) Способ лечения ожогов глаз
Ignjatović Postoperative Complications After Vitreoretinal Surgery
RU2080844C1 (ru) Способ профилактики послеоперационной цилиохориоидальной отслойки

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid